BELLUS Health and its partner Auven therapeutics have announced that the KIACTATM event-driven phase 3 confirmatory study for the treatment of AA amyloidosis, has met its completion target of 120 patient events linked to the deterioration of kidney function. Top line data will take a few months to be compiled after all remaining patients have completed final study visits. The trial has spanned 50 sites worldwide. It is only once this process is complete that the data from the placebo controll
22 Jan 2016
Phase 3 confirmatory trial complete
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Phase 3 confirmatory trial complete
Blue Star Capital Plc (BLU:LON) | 0.0 0 0.0% | Mkt Cap: 1.66m
- Published:
22 Jan 2016 -
Author:
Derren Nathan -
Pages:
6
BELLUS Health and its partner Auven therapeutics have announced that the KIACTATM event-driven phase 3 confirmatory study for the treatment of AA amyloidosis, has met its completion target of 120 patient events linked to the deterioration of kidney function. Top line data will take a few months to be compiled after all remaining patients have completed final study visits. The trial has spanned 50 sites worldwide. It is only once this process is complete that the data from the placebo controll